Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 4 7Phase 3 4Phase 2/3 3Phase 2 2Phase 1/2 1

Status

Unknown 2Completed 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other neoplasm 1Endocrine 1

Conditions

Non-functioning Pituitary Adenoma 1Intrathecal Dexmedetomidine 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Dexmedetomidine × Clear all
NCT05005715 2021-08-13

Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery

Seoul National University Hospital

Phase 2 Unknown
64 enrolled
Endocrine

Non-functioning Pituitary Adenoma

NCT02861716 2018-04-10

Intrathecal Dexmedetomidine Versus Fentanyl With Bupivacaine in Children Undergoing Major Abdominal Cancer Surgery

South Egypt Cancer Institute

Phase 2 Unknown
60 enrolled
Other neoplasm

Intrathecal Dexmedetomidine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡